Entrada Therapeutics (TRDA)
NasdaqMarket Closed
6.42USD
6.42 USD
−0.69(-9.70%)
Pre-market
Last updated
- Market Cap
- $277,618,450
- P/E
- —
- P/FCF
- —
- P/S
- 59.24
- Enterprise Value
- $178,338,450
- Sector
- —
- Industry
- —
- Address
- ONE DESIGN CENTER PLACE, BOSTON, MA, 02210
globenewswire.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jun 2026, 04:30 AM
yahoo.com
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?
08 May 2026, 04:04 AM
yahoo.com
Sector Update: Health Care Stocks Softer Late Afternoon
08 May 2026, 03:44 AM
yahoo.com
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
05 May 2026, 21:12 PM
yahoo.com
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
05 May 2026, 05:10 AM
yahoo.com
Sector Update: Health Care Stocks Softer Late Afternoon
07 Apr 2026, 03:50 AM
yahoo.com
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
19 Mar 2026, 02:08 AM
nasdaq.com
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
19 Mar 2026, 02:08 AM
yahoo.com
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
19 Mar 2026, 01:54 AM
globenewswire.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Mar 2026, 05:30 AM
yahoo.com
Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates
26 Feb 2026, 08:25 AM
yahoo.com
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
24 Feb 2026, 22:40 PM
yahoo.com
Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates
06 Feb 2026, 07:00 AM
yahoo.com
Techne (TECH) Beats Q2 Earnings and Revenue Estimates
04 Feb 2026, 20:40 PM
globenewswire.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Dec 2025, 05:30 AM
nasdaq.com
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company
30 Nov 2025, 02:48 AM
yahoo.com
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company
30 Nov 2025, 02:48 AM
yahoo.com
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?
19 Nov 2025, 03:11 AM
yahoo.com
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out
19 Nov 2025, 02:55 AM
yahoo.com
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
06 Nov 2025, 21:30 PM
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $277,618,450
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $178,338,450
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.19
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 59.24
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -1.03
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 38.06
- EPS
- -4.26
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -$134,997,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -71.02%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -55.47%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 10.89
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 10.89
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 4.65
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $329,059
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 7.13
Income Statement
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Revenue | 898K | 875K | 1.3M | 1.61M | 1.95M |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 898K | 875K | 1.3M | 1.61M | 1.95M |
| Operating income | -44.96M | -42.3M | -42.21M | -47.05M | -46.85M |
| EBITDA | -44.12M | -41.5M | -41.32M | -45.82M | -45.82M |
| Net income | -42.76M | -39.72M | -39.16M | -44.13M | -43.1M |
| Income taxes | 35K | 38K | 92K | 654K | 178K |
| Interest expense | 0 | 0 | 0 | 0 | 0 |
| Other operating expenses | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 45.86M | 43.18M | 43.51M | 48.67M | 48.8M |
| Basic EPS | -1.01 | -0.95 | -0.94 | -1.06 | -1.04 |
| Diluted EPS | -1.01 | -0.95 | -0.94 | -1.06 | -1.04 |
Balance Sheet
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Total assets | 298.88M | 335.52M | 377.38M | 412.9M | 448.78M |
| Total liabilities | 65.47M | 64.66M | 71.25M | 72.18M | 69.28M |
| Total equity | 233.41M | 270.85M | 306.13M | 340.72M | 379.51M |
| Cash & equivalents | 99.28M | 76.44M | 90.39M | 93.29M | 72.48M |
| Current assets | 232.7M | 266.87M | 306.25M | 338.26M | 369.15M |
| Current liabilities | 21.37M | 19.2M | 24.45M | 24.02M | 19.8M |
| Accounts payable | 3.75M | 2.93M | 2.29M | 3.17M | 1.86M |
| Receivables | 816K | 787K | 1.18M | 1.2M | 1.18M |
| Inventories | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
Cash Flow
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Operating cash flow | -32.46M | -41.7M | -32.2M | -28.31M | -29.49M |
| Investing cash flow | 54.95M | 26.99M | 29.12M | 49.11M | 33.8M |
| Financing cash flow | 350K | 100K | 192K | 8K | 337K |
| Change in cash | 22.84M | -14.61M | -2.89M | 20.8M | 4.65M |
| Net income | -42.76M | -39.72M | -39.16M | -44.13M | -43.1M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13D/A — Entrada Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Entrada Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Entrada Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014, L.P. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 GP LLC | View Filing | |
| form 4 | Form 4 — Foley Todd | View Filing | |
| form 4 | Form 4 — MPM Asset Management Investors BV2014 LLC | View Filing | |
| form 4 | Form 4 — EVNIN LUKE | View Filing | |
| form 4 | Form 4 — MPM BIOVENTURES 2018 (B), L.P. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 (B), L.P. | View Filing | |
| form 4 | Form 4 — GADICKE ANSBERT | View Filing | |
| form 4 | Form 4 — MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2018 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2018 GP LLC | View Filing | |
| form 4 | Form 4 — MPM BIOVENTURES 2018, L.P. | View Filing | |
| form 4 | Form 4 — MPM Asset Management Investors BV2014 LLC | View Filing | |
| form 4 | Form 4 — EVNIN LUKE | View Filing | |
| form 4 | Form 4 — MPM BIOVENTURES 2018 (B), L.P. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 (B), L.P. | View Filing | |
| form 4 | Form 4 — GADICKE ANSBERT | View Filing | |
| form 4 | Form 4 — MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014, L.P. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 GP LLC | View Filing | |
| form 4 | Form 4 — Foley Todd | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2018 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2018 GP LLC | View Filing | |
| form 4 | Form 4 — MPM BIOVENTURES 2018, L.P. | View Filing | |
| form 4 | Form 4 — MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014, L.P. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 GP LLC | View Filing | |
| form 4 | Form 4 — Foley Todd | View Filing | |
| form 4 | Form 4 — MPM Asset Management Investors BV2014 LLC | View Filing | |
| form 4 | Form 4 — EVNIN LUKE | View Filing | |
| form 4 | Form 4 — MPM BIOVENTURES 2018 (B), L.P. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 (B), L.P. | View Filing | |
| form 4 | Form 4 — GADICKE ANSBERT | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2018 GP LLC | View Filing | |
| form 4 | Form 4 — MPM BIOVENTURES 2018, L.P. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2018 LLC | View Filing | |
| edgar index | 4 — Entrada Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Entrada Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Entrada Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Entrada Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Entrada Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Entrada Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Foley Todd | View Filing | |
| form 4 | Form 4 — MPM Asset Management Investors BV2014 LLC | View Filing | |
| form 4 | Form 4 — EVNIN LUKE | View Filing | |
| form 4 | Form 4 — MPM BIOVENTURES 2018 (B), L.P. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 (B), L.P. | View Filing | |
| form 4 | Form 4 — GADICKE ANSBERT | View Filing | |
| form 4 | Form 4 — MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014, L.P. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 GP LLC | View Filing | |
| form 4 | Form 4 — MPM BIOVENTURES 2018, L.P. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2018 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2018 GP LLC | View Filing | |
| form 4 | Form 4 — EVNIN LUKE | View Filing | |
| form 4 | Form 4 — MPM BIOVENTURES 2018 (B), L.P. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 (B), L.P. | View Filing | |
| form 4 | Form 4 — GADICKE ANSBERT | View Filing | |
| form 4 | Form 4 — MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014, L.P. | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2014 GP LLC | View Filing | |
| form 4 | Form 4 — Foley Todd | View Filing | |
| form 4 | Form 4 — MPM Asset Management Investors BV2014 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2018 LLC | View Filing | |
| form 4 | Form 4 — MPM BioVentures 2018 GP LLC | View Filing | |
| form 4 | Form 4 — MPM BIOVENTURES 2018, L.P. | View Filing | |
| form 4 | Form 4 — Doshi Dipal | View Filing |
Interval